Adicet Bio, Inc. 8-K

What Happened
Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2025 via a press release dated March 12, 2026. The company furnished the press release as Exhibit 99.1 to its Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The Form 8-K was signed by CFO Nick Harvey on March 12, 2026.

Key Details

• Filing date: March 12, 2026 (8-K reporting results for quarter and year ended Dec 31, 2025).
• Press release: Furnished as Exhibit 99.1 to the 8-K (the document provides the detailed financial results).
• Disclosure status: Information is being furnished — not “filed” — and is not incorporated by reference into other SEC filings.
• Authorized signature: Form signed by Nick Harvey, Chief Financial Officer.

Why It Matters
This 8-K notifies investors that Adicet has publicly reported its recent quarterly and annual financial performance; the press release contains the specific financial figures and operating highlights investors will use to assess revenue, profitability, cash position, and trends. Because the release is furnished (not filed), it informs the market but does not expand Section 18 liability or automatically become part of other SEC filings. Investors should review Exhibit 99.1 (the press release) for the full figures and management commentary before making decisions.